OBIO — Orchestra Biomed Holdings Income Statement
0.000.00%
- $248.44m
- $166.83m
- $2.64m
Annual income statement for Orchestra Biomed Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 8-K | 8-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5.7 | -0.782 | 3.53 | 2.76 | 2.64 |
| Cost of Revenue | |||||
| Gross Profit | 5.56 | -0.981 | 3.32 | 2.57 | 2.43 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 24.5 | 21 | 36.9 | 55.4 | 66.9 |
| Operating Profit | -18.8 | -21.8 | -33.3 | -52.7 | -64.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -21.4 | -23 | -33.6 | -49.1 | -61 |
| Net Income After Taxes | -21.4 | -23 | -33.6 | -49.1 | -61 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -21.4 | -23 | -33.6 | -49.1 | -61 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -21.4 | -23 | -35.6 | -49.1 | -61 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.675 | -0.728 | -1.1 | -1.44 | -1.66 |
| Dividends per Share |